Cyagen

Cyagen is a contract research organization specializing in custom animal models, cell lines, and viral vector packaging for preclinical research. The company offers genetically engineered rodent models through techniques including TurboKnockout gene targeting, CRISPR-based editing, transgenic generation, and Cre-ESC manipulation. Its product portfolio includes humanized mouse models (HUGO-GT, HUGO-Ab), disease-specific models for oncology, neurology, metabolism, and immunology, as well as custom iPSC, knockout, and knockin cell lines. Cyagen also provides AAV, lentivirus, and adenovirus packaging services for gene therapy and vaccine R&D, along with antibody discovery platforms utilizing fully human antibody mice and AI-powered screening. Founded in 2005 and headquartered in Santa Clara, California, the company has raised approximately $40.5 million in Series B funding from investors including GF Xinde Investment Management, China Merchants Securities, GF Qianhe Investment, and Guanghua Venture Capital.